Codexis, Inc.
CDXS
NASDAQ·Healthcare·Biotechnology·Mkt cap $157.0M
$1.46
▲ +2.82%
P/E
-4.35
Mkt Cap
$157.0M
52-Wk Range
$0.96–$2.98
52-Week Range
$0.96 - $2.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 40.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary CodeEvolver protein engineering platform enabling rapid biocatalyst development
- Extensive enzyme library and screening capabilities for accelerated customer solutions
- Established relationships with major pharmaceutical manufacturers and chemical producers
- Patent portfolio protecting core enzyme designs and engineering methodologies
- Expertise in directed evolution and synthetic biology with 20+ years of R&D
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Stable outlook
Increasing pharmaceutical industry adoption of biocatalysts for cost reduction and sustainability
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-44.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CDXS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 11, 2026
Reported EPS of -$0.13 vs -$0.14 consensus (+8.2% surprise). Revenue of $14.9M vs $13.8M expected (+7.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.2%
Revenue trend · last 8Q
—
-19%
-56%
+92%
-33%
+81%
+102%
-3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$12.8M
$21.5M
$7.5M
$15.3M
$8.6M
$38.9M
$15.2M
$14.9M
Margins · last 8Q
Gross
84.8%
Operating
-75.3%
Profit
-80.5%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Benchmark · Aug 20, 2026
vs Industry
How CDXS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related